Plus: Xtalpi, Solid and Arcus all raise cash

BioCentury’s final Public Equity Report of the year tallies up fundraising activity

Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more

PDAC candidates mostly small molecules against old targets, as a pair of radiopharmaceuticals competes in pancreatic neuroendocrine setting

Mega-round for Alentis spotlights French firm’s investment style 

Plus: M&A deals by Lantheus, Illumina; and over half a dozen new partnerships

Beyond the headlines at ASCO and AACR were a set of less traveled cancer targets, including neuronal proteins hijacked by solid tumors

French biotech to pursue novel targets with ADCs incorporating new and old payloads

German biotech raised series B2 round in March to push two highly stable ADC candidates into the clinic, and discover new payloads

Singapore biotech aiming to overcome drug resistance by creating therapies carrying multiple payloads with orthogonal MoAs